EWA
IPSC icon

EverSource Wealth Advisors’s Century Therapeutics IPSC Stock Holding History

EverSource Wealth Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28
Closed -$14 – 4346
2025
Q3 		$14 Sell
28
-427
-94% -$230 ﹤0.01% 4291
2025
Q2 		$254 Buy
455
+414
+1,010% +$222 ﹤0.01% 4026
2025
Q1 		$20 Buy
+41
New +$31 ﹤0.01% 3966

Other funds holding IPSC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EverSource Wealth Advisors's IPSC Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Century Therapeutics (IPSC) in Q4 2025, closing a stake of 28 shares — an estimated $14 sold.

EverSource Wealth Advisors first reported a position in IPSC in Q1 2025 and held it in 3 quarters. The position peaked at $254 in Q2 2025. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Century Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 28 Century Therapeutics shares in Q4 2025, an estimated $14.
  • EverSource Wealth Advisors first reported a position in Century Therapeutics in Q1 2025 and held it in 3 quarters.
  • EverSource Wealth Advisors's Century Therapeutics position peaked at $254 in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.